OnKure Therapeutics (NASDAQ:OKUR - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings estimates for shares of OnKure Therapeutics in a research report issued on Thursday, October 17th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($1.03) for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for OnKure Therapeutics' current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for OnKure Therapeutics' Q4 2024 earnings at ($1.08) EPS, FY2024 earnings at ($3.87) EPS and FY2025 earnings at ($4.70) EPS.
A number of other equities research analysts have also recently weighed in on OKUR. Oppenheimer assumed coverage on shares of OnKure Therapeutics in a report on Thursday, October 10th. They issued an "outperform" rating and a $35.00 price objective on the stock. Lifesci Capital upgraded OnKure Therapeutics to a "strong-buy" rating in a research note on Thursday, October 10th.
View Our Latest Report on OKUR
OnKure Therapeutics Trading Up 0.2 %
OnKure Therapeutics stock traded up $0.04 on Monday, hitting $18.55. 84,399 shares of the stock traded hands, compared to its average volume of 27,990. OnKure Therapeutics has a 1 year low of $9.80 and a 1 year high of $82.90. The firm has a market capitalization of $61.96 million, a P/E ratio of -1.12 and a beta of 0.21.
OnKure Therapeutics Company Profile
(
Get Free Report)
Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.
Featured Stories
Before you consider OnKure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OnKure Therapeutics wasn't on the list.
While OnKure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
